GlobeNewswire: Clearside Biomedical, Inc. Contains the last 10 of 235 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T05:31:45ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/18/2847674/0/en/Clearside-Biomedical-Appoints-Victor-Chong-M-D-MBA-as-Chief-Medical-Officer.html?f=22&fvtc=4&fvtv=28861Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer2024-03-18T11:05:00Z<![CDATA[Industry Veteran with Extensive Experience in Retinal Disease Research and Strong Track Record in Advancing Programs Through Clinical Development Industry Veteran with Extensive Experience in Retinal Disease Research and Strong Track Record in Advancing Programs Through Clinical Development]]>Victor Chong, M.D., MBA was appointed as Chief Medical Officer for Clearside Biomedical.Victor Chong, M.D., MBA https://www.globenewswire.com/news-release/2024/03/12/2845009/0/en/Clearside-Biomedical-Announces-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=28861Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update2024-03-12T20:05:00Z<![CDATA[- Phase 2b ODYSSEY Wet AMD Trial Remains on Track with Topline Data Expected in Q3 2024 -]]>https://www.globenewswire.com/news-release/2024/02/29/2837845/0/en/Clearside-Biomedical-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provide-Corporate-Update-on-Tuesday-March-12-2024.html?f=22&fvtc=4&fvtv=28861Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 20242024-02-29T12:05:00Z<![CDATA[ALPHARETTA, Ga., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its fourth quarter and full year 2023 financial results will be reported on Tuesday, March 12, 2024 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.]]>https://www.globenewswire.com/news-release/2024/02/07/2825131/0/en/Clearside-Biomedical-Announces-Pricing-of-15-Million-Registered-Direct-Offering.html?f=22&fvtc=4&fvtv=28861Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering2024-02-07T13:00:00Z<![CDATA[ALPHARETTA, Ga., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (“Clearside” or the “Company”) (NASDAQ: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that it has entered into a securities purchase agreement with institutional investors and an existing stockholder, providing for the purchase and sale of 11,111,111 shares of common stock and accompanying warrant to purchase up to 11,111,111 shares of common stock in a registered direct offering. The offer price for one share of common stock and accompanying warrant to purchase one share of common stock will be $1.35. The warrants have an exercise price of $1.62 per share, will be exercisable six months from the issuance date and will have a term of five years from the initial exercise date. The offering is expected to close on or about February 9, 2024, subject to the satisfaction of customary closing conditions.]]>https://www.globenewswire.com/news-release/2023/12/14/2796150/0/en/Clearside-Biomedical-Reports-Significant-Progress-in-ODYSSEY-Phase-2b-Trial-of-CLS-AX-in-Wet-AMD.html?f=22&fvtc=4&fvtv=28861Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD2023-12-14T12:05:00Z<![CDATA[- CLS-AX is a Highly Potent Tyrosine Kinase Inhibitor Delivered Suprachoroidally Using Clearside’s SCS Microinjector® -]]>https://www.globenewswire.com/news-release/2023/11/13/2779441/0/en/Clearside-Biomedical-Announces-Third-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=28861Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update2023-11-13T21:05:00Z<![CDATA[- New Licensing Partnership with BioCryst Pharmaceuticals Expands Clearside’s Proprietary Suprachoroidal Injection Platform to Plasma Kallikrein Inhibitor -]]>https://www.globenewswire.com/news-release/2023/11/08/2776085/0/en/Clearside-Biomedical-to-Participate-in-Fireside-Chat-at-the-Stifel-2023-Healthcare-Conference.html?f=22&fvtc=4&fvtv=28861Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference2023-11-08T12:05:00Z<![CDATA[ALPHARETTA, Ga., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, will participate in a fireside chat at the Stifel 2023 Healthcare Conference on Wednesday, November 15, 2023 at 8:35 a.m. ET in New York, NY.]]>https://www.globenewswire.com/news-release/2023/11/07/2775672/0/en/Clearside-Biomedical-s-Versatile-Suprachoroidal-Injection-Platform-Highlighted-in-Four-Ophthalmic-Indications-in-Clinical-Data-Presentations-at-AAO-2023-Annual-Meeting.html?f=22&fvtc=4&fvtv=28861Clearside Biomedical’s Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual Meeting2023-11-07T21:20:00Z<![CDATA[Robust Safety Profile and Encouraging Efficacy Data Utilizing SCS Microinjector® Featured in Multiple Data Presentations Robust Safety Profile and Encouraging Efficacy Data Utilizing SCS Microinjector® Featured in Multiple Data Presentations]]>https://www.globenewswire.com/news-release/2023/11/02/2772134/0/en/Clearside-Biomedical-Announces-Presentations-at-the-American-Academy-of-Ophthalmology-2023-Annual-Meeting.html?f=22&fvtc=4&fvtv=28861Clearside Biomedical Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting2023-11-02T11:05:00Z<![CDATA[- Clinical Data Utilizing Clearside’s Suprachoroidal Delivery Technology to be Featured in Multiple Oral and Poster Presentations - - Clinical Data Utilizing Clearside’s Suprachoroidal Delivery Technology to be Featured in Multiple Oral and Poster Presentations -]]>https://www.globenewswire.com/news-release/2023/11/01/2770999/0/en/Clearside-Biomedical-Completes-Recruitment-in-ODYSSEY-Phase-2b-Clinical-Trial-of-CLS-AX-in-Wet-AMD.html?f=22&fvtc=4&fvtv=28861Clearside Biomedical Completes Recruitment in ODYSSEY Phase 2b Clinical Trial of CLS-AX in Wet AMD2023-11-01T11:05:00Z<![CDATA[- Successful Completion of Recruitment Driven by Strong Clinical Site Participation and Investigator Support -]]>